CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...